These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 9754988)
1. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity. Bathum L; Andersen-Ranberg K; Boldsen J; Brøsen K; Jeune B Eur J Clin Pharmacol; 1998 Jul; 54(5):427-30. PubMed ID: 9754988 [TBL] [Abstract][Full Text] [Related]
2. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152 [TBL] [Abstract][Full Text] [Related]
3. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072 [TBL] [Abstract][Full Text] [Related]
4. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Ford GA; Wood SM; Daly AK Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124 [TBL] [Abstract][Full Text] [Related]
5. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309 [TBL] [Abstract][Full Text] [Related]
6. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000 [TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145 [TBL] [Abstract][Full Text] [Related]
8. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. de Leon J; Susce MT; Murray-Carmichael E Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600 [TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584 [TBL] [Abstract][Full Text] [Related]
10. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013 [TBL] [Abstract][Full Text] [Related]
11. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Yamada H; Dahl ML; Lannfelt L; Viitanen M; Winblad B; Sjöqvist F Eur J Clin Pharmacol; 1998 Aug; 54(6):479-81. PubMed ID: 9776439 [TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065 [TBL] [Abstract][Full Text] [Related]
13. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367 [TBL] [Abstract][Full Text] [Related]
14. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336 [TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181 [TBL] [Abstract][Full Text] [Related]
16. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294 [TBL] [Abstract][Full Text] [Related]
17. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041 [TBL] [Abstract][Full Text] [Related]
18. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905 [TBL] [Abstract][Full Text] [Related]
19. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032 [TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]